Figure 1. CS particles stimulated CD4+TRM cell emergence and expansion along with silicosis
progression.
(A) Schematic showed CD45-APC-Cy7 antibody intravenous (i.v. )
injection to distinguish tissue-resident or circulating leukocytes.
Circulating leukocytes were labeled. (B) Flow cytometry (FC) analysis of
pulmonary CD4+ TRM cells (CD45inject–CD44+) and
TEM (CD45inject+CD44+) cells.
Percentages and counts of the CD4+ TRMcells were compared at the
indicated time points (n = 5). W, week. (C)
Representative
FC analysis of CD4+ TRM cells for
CD69, CD103 and CXCR6 expression
respectively. (D) FC analysis of CD4+TRM cells for CD69 and CD103 expression. The graph
showed percentages and counts of
CD69+CD103– (upper) and
CD69+CD103+ subsets (lower) in
CD4+ TRM cells of saline or CS-treated
mice at the specified time points (n = 5). (E) FC analysis of lung
circulating TEM cells for CD69 and CD103 expression of
saline or CS-treated mice at specified time points. The bar graph
illustrated ratios of CD69+ in circulating
CD4+ TEMcells (n = 4). (F)
FC analysis of splenic
TEM cells for CD69 and CD103. The graph compared
percentages of CD69+ on
splenic CD4+TEM cells of saline or CS-treated mice (n = 6). The bar
graphs are the combined results of at least three independent
experiments. Individual mice are plotted on the graphs. Values are
reported as the mean ± SD. P value was determined by one-way
ANOVA followed by Tukey’s test.